Press Releases GSK plc

Equities

GSK

GB00BN7SWP63

Market Closed - London S.E. Other stock markets 11:35:07 2024-05-28 am EDT			5-day change	1st Jan Change
1,740 ^GBX	-1.94%		-0.91%	+19.98%

03:40pm	CureVac, GSK Begin Dosing in Phase 2 Study for Seasonal Influenza Vaccine Candidate	MT
May. 27	US, European nations consider vaccinating workers exposed to bird flu	RE

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Statement: Zantac (ranitidine) litigation - Valadez and Williams cases - Form 6-K	May. 24	PU
New data at ASCO showcases the transformational potential of GSK's oncology portfolio \| GSK	May. 24	AQ
Statement: Zantac (ranitidine) litigation - Valadez and Williams cases \| GSK	May. 24	AQ
GSK : New data at ASCO showcases the transformational potential of GSK's oncology portfolio	May. 23	PU
Statement: Zantac (ranitidine) litigation - Valadez and Williams cases	May. 23	PU
GSK announces positive results from phase III severe asthma trials of depemokimab \| GSK	May. 21	AQ
GSK : announces positive results from phase III severe asthma trials of depemokimab - Form 6-K	May. 21	PU
GSK : completes sale of remaining shares in Haleon - Form 6-K	May. 17	PU
GSK : to become a founding partner of Fleming Initiative to fight antimicrobial resistance (AMR)	May. 15	PU
GSK : Director/Pdmr Shareholding - Form 6-K	May. 14	PU
GSK : BLOCK LISTING SIX MONTHLY RETURN - Form 6-K	May. 13	PU
BioVersys Announces Expansion of Strategic Collaboration With GSK and Extension of Its Series C Round by CHF 12.3 Million	May. 07	AQ
GSK : Q1 2024 results transcript	May. 02	PU
GSK : Q1 2024 results slides	May. 02	PU
GSK : Q1 2024 results infographic	May. 02	PU
Glaxo: Q1 Earnings Snapshot	May. 01	AQ
US FDA accepts for priority review GSK's application for an expanded indication of Jemperli (dostarlimab) plus chemotherapy to include all adult patients with primary advanced or recurrent endometrial cancer \| GSK	Apr. 24	AQ
GSK : Director/Pdmr Shareholding - Form 6-K	Apr. 19	PU
EAGLE-1 phase III data show potential for gepotidacin as a new oral treatment option for uncomplicated urogenital gonorrhoea (GC) amid growing resistance to existing treatments \| GSK	Apr. 17	AQ
New long-term data show Shingrix continues to provide high protection against shingles in adults aged 50 and over for more than a decade \| GSK	Apr. 17	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

GSK plc : Back on track

May 03, 2024 at 05:17 am EDT

GSK PLC : Encouraging start to 2024; guidance raised

May 01, 2024 at 11:38 am EDT